IP Verse

Oral Formulations Of Deferasirox - EP2964202

The patent EP2964202 was granted to Novartis on May 31, 2023. The application was originally filed on Mar 6, 2014 under application number EP14710654A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2964202

NOVARTIS
Application Number
EP14710654A
Filing Date
Mar 6, 2014
Status
Patent Maintained As Amended
Apr 28, 2023
Grant Date
May 31, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

INVOKAT SERVICESJul 31, 2019MUTLUADMISSIBLE
HGFJul 30, 2019HGFADMISSIBLE
TEVA PHARMACEUTICALSJul 23, 2019ELKINGTON AND FIFEADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2005097062
INTERNATIONAL-SEARCH-REPORTWO2009130604
INTERNATIONAL-SEARCH-REPORTWO2010143006
INTERNATIONAL-SEARCH-REPORTWO9749395
OPPOSITIONEP2964202
OPPOSITIONEP3124018
OPPOSITIONUS2011097413
OPPOSITIONWO2004035026
OPPOSITIONWO2005097062
OPPOSITIONWO2007045445
OPPOSITIONWO2009067557
OPPOSITIONWO2009106824
OPPOSITIONWO2010035282
OPPOSITIONWO2010143006
OPPOSITIONWO2012042224
OPPOSITIONWO2014136079
OPPOSITIONWO2017158559

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Revision of Monograph on Tablets, Final text for addition to The International Pharmacopoeia", WORLD HEALTH ORGANISATION DOCUMENT QAS/09.324/FINAL, (20110300), pages 1 - 10, XP055522163
OPPOSITION- Anonymous, "Zovirax® Oral Presentations", Product leaflet of Ministery of Health, (20110600), pages 1 - 11, XP055522173
OPPOSITION- "Background review for sodium laurilsulfate used as an excipient", European Medicines Agency , EMA/CHMP/351898/2014, Committee for Human Medicinal Products (CHMP, (20150723), pages 1 - 18, XP055393943
OPPOSITION- EXJADE: EPAR, "Product Information Annex I", European Medicines Agency, (20090820), XP055626455
OPPOSITION- "Fachinformation Ferriprox 500 mg/ 1000 mg Filmtabletten;", SObI, (20170400), XP055626451
OPPOSITION- Loyd V. Allen et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, (20110000), pages 128 - 132, XP055276588
OPPOSITION- M. LANDIN et al., "Comparison of two Varieties of Microcrystalline Cellulose as Filler- Binders II. Hydrochlorothiazide Tablets", Drug Development and Industrial Pharmacy, (19930000), vol. 19, no. 10, pages 1211 - 1220, XP055522166
OPPOSITION- Novartis, "Jadenu", Product Monograph, (20181126), pages 1 - 52, XP055629889
OPPOSITION- "Poloxamer", ROWE et al., Handbook of pharmaceutical excipients, PhP, (20090000), pages 506 - 509, 651-653, ISBN 978-0-85369-792-3, XP055629883
OPPOSITION- "WHO", Final text for addition to The International Pharmacopoeia Revision of Monograph on Tablets, (20110300), XP055522163
OPPOSITION- EADALA et al., "Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions", Alimentary Pharmacology and Therapeutics, vol. 29, no. 6, (20090000), pages 677 - 687, URL: https://doi.org/10.1111/j.1365-2036.2008.03889.x, XP055629881
OPPOSITION- DEY P. et al., "Orodispersible tablets: A new trend in drug delivery", J. Nat. Sci. Biol. Med., (20100700), vol. 1, no. 1, pages 2 - 5, XP055629865

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents